# **NISSHA** Financial Results for FY2018.12

February 14, 2019 Nissha Co., Ltd. President and CEO Junya Suzuki

# Highlights

#### FY2018.12 Results

- Increased in both profit and income YoY (1USD=JPY109)
  - Net sales 207.4 billion yen, EBITDA 17.3 billion yen, Operating profit 8 billion yen, Ordinary profit 7.3 billion yen, Net profit 4.3 billion yen
  - Devices: Demand expanded in the 2<sup>nd</sup> half but sharply flopped in December.
  - Industrial Materials: Demand for automotive and metallized paper progressed stably.
     Production loss in overseas molding factories occurred.
  - Medical Technologies: Business size up through the company acquisitions

#### FY2019.12 Forecast

- Increase in profit and decrease in income (No company acquisition included. 1USD=105JPY)
  - Net sales 195 billion yen, EBITDA 18.8 billion yen, Operating profit 8.5 billion yen, Ordinary profit 7.8 billion yen, Net profit 6.0 billion yen
  - Devices: Slow trend in the 1<sup>st</sup> half, rapid recovery in the 2<sup>nd</sup> half.
  - Acceleration of growth strategy: Medical Devices, High-function Packaging Materials, Automotive

#### Topics

- 2 Independent Outside Directors to be changed (a resolution for the shareholders meeting on March 22, 2019. Ratio of outside directors to be flat as 4/9)
- No renewal of countermeasures against a large scale purchase of shares
- Dividend in 2019 anticipated at JPY35 per share, including memorial dividend (JPY5 per share) for the 90th anniversary
- Completion of the reorganization of Information and Communication on January 7, 2019

## FY2018.12 Results EMPOWERING YOUR VISION Increase both in profit and income. Net sales reached a record high. Over 20% YoY growth in net sales of Medical Technologies (Millions of JPY)

|                         |                               | 2017<br>(JanDec.)<br>Results | FY2018.12<br>(JanDec.)<br>Results | YoY*                  |
|-------------------------|-------------------------------|------------------------------|-----------------------------------|-----------------------|
| Net sales               |                               | 193,481                      | <b>√</b> 207,404                  | +7.2%                 |
|                         | Industrial Materials          | 49,409                       | 47,124                            | -4.6%                 |
|                         | Devices                       | 111,084                      | 123,541                           | +11.2%                |
|                         | Medical Technologies          | 18,195                       | 22,351                            | <mark>√</mark> +22.8% |
|                         | Information and Communication | 14,445                       | 13,935                            | -3.5%                 |
|                         | Other                         | 347                          | 452                               | +30.3%                |
| EBI                     | TDA                           | 15,100                       | 17,343                            | +14.9%                |
| EBIT                    | DA margin                     | 7.8%                         | 8.4%                              | +0.6pt                |
| Operating profit        |                               | 4,004                        | <b>√</b> 8,071                    | +101.5%               |
| Operating profit margin |                               | 2.1%                         | 3.9%                              | +1.8pt                |
| Ordinary profit         |                               | 4,936                        | 7,370                             | +49.3%                |
| Net profit              |                               | 2,681                        | 4,308                             | +60.7%                |
| Forex                   |                               | ¥111/\$                      | ¥109/\$                           |                       |



The term of FY2017.12 was nine months in accordance with the fiscal year end date change. Therefore, business results for FY2018.12 are compared with those for the same period of the previous year (January 1, 2017 to December 31, 2017).

## FY2018.12 Oct.-Dec. Results

NISSHA

Profitability improved in YoY basis and sustained in QoQ basis


(Millions of JPY)

|           |                                  | FY2017.12 FY2018.12 |                    | FY2018.12          |        |        |
|-----------|----------------------------------|---------------------|--------------------|--------------------|--------|--------|
|           |                                  | OctDec.<br>Results  | JulSep.<br>Results | OctDec.<br>Results | YoY    | QoQ    |
| Net sales |                                  | 64,503              | 68,318             | 66,544             | +3.2%  | -2.6%  |
|           | Industrial Materials             | 13,088              | 11,180             | 12,606             | -3.7%  | +12.8% |
|           | Devices                          | 41,917              | 48,029             | 43,500             | +3.8%  | -9.4%  |
|           | Medical<br>Technologies          | 5,085               | 6,028              | 6,336              | +24.6% | +5.1%  |
|           | Information and<br>Communication | 4,310               | 2,967              | 3,974              | -7.8%  | +33.9% |
|           | Others                           | 103                 | 113                | 130                | +26.2% | +15.0% |
| EB        | ITDA                             | 7,353               | 8,834              | 8,377              | +13.9% | -5.2%  |
| EBI       | TDA margin                       | 11.4%               | 12.9%              | <b>√</b> 12.6%     | +1.2pt | -0.3pt |
| Op        | erating profit                   | 4,439               | 6,434              | 6,113              | +37.7% | -5.0%  |
| Ope       | rating profit margin             | 6.9%                | 9.4%               | ✓ 9.2%             | +2.3pt | -0.2pt |
| Ord       | dinary profit                    | 5,362               | 7,349              | 5,975              | +11.4% | -18.7% |
| Ne        | t profit                         | 4,893               | 7,205              | 3,857              | -21.2% | -46.5% |
| Forex     |                                  | ¥111/\$             | ¥110/\$            | ¥111/\$            |        |        |

# **Industrial Materials**

Demand for automotive and metallized paper progressed steadily






NISSHA CONFIDENTIAL PROPRIETARY


### **Devices**

#### Q4 results underperformed to Q3 results due to sharp drop in demand in December




# Medical Technologies

#### Business size up through the acquisitions of 3 companies



# **Information and Communication**



# Update on The 6<sup>th</sup> Medium-term Business Plan (2018-2020)




## Focused markets in the Plan



#### nissha

# Strategy in FY2019, the 2<sup>nd</sup> year of the 6<sup>th</sup> Medium-term Business Plan

 To promote growth in Medical Devices, High-function Packaging Materials, and Automotive, through M&A as an option  To sustain and seek for profitability and efficiency in IT





M&A budget for the 6th Medium-term Business Plan Total 31.5 billion JPY (2018-2020, 3 years)




#### **Medical Devices**

### EMPOWERING YOUR VISION Accelerate growth for Medical Devices and move in high gear for DDS

#### Medical Devices

- Contract manufacturing: To extend development and design capabilities
- Own brand: To enrich distinctive product lineup

- Drug Delivery System (DDS)
  - Business opportunity: Dosage form change from general dosage like pills, injection, etc Microneedle



#### High-function Packaging Materials

#### EMPOWERING YOUR VISION

# Focus on sustainable packaging material

- Demand increase for recyclable packages in EU and other regions
- More business opportunities for metallized paper
  - Metallized paper is sustainable and premium packaging material
  - Overwhelming market share in EU and in North America **Q**Rmetallizing





- To bring more new packaging materials into market
  - High-function and sustainable





Printing





✓ Laminating



✓ Molding








Nissha's Core Technologies

#### Automotive

#### EMPOWERING YOUR VISION

# Introduce new products for automotive



# Sustain profitability and efficiency

## Business opportunity

| Number of models             | 2017  | 2018     | 2019     |  |
|------------------------------|---|----------|----------|--|
| Number of models             | 2017 model  |          |          |  |
|                              | 201   | 8 models |          |  |
| Trend<br>Display gets larger |   | 2019     | 9 models |  |
|                              | Number of models with our touch sensor film has been increasing |          |          |  |

## • Our advantages

### Technology

TΤ

- Narrower frame
- Thinner touch film
- Advancing optical quality
- Production Quality Supply capacity capacity Smooth and quick • JV with Lens production launch Technology
- Good reputation
  - from the supply
- chain partners

#### Nissha and Lens Technologies Launch in 2019



# Seeking for both corporate value and shareholder value

| Investment<br>for growth | <ul> <li>M&amp;A: Medical Devices, High-function Packaging<br/>Materials, Automotive</li> <li>Budget for 3 years: JPY 31.5 billion</li> <li>Capital investment: Mainly for maintenance</li> <li>* 3 years: Term for the 6<sup>th</sup> Medium-term Business Plan</li> </ul> |
|--------------------------|---|
|                          |   |
|                          |   |

|                       | <ul> <li>Dividend</li> <li>2019 forecast: JPY30+JPY5 (90<sup>th</sup> anniversary)</li> </ul>                                   |
|-----------------------|---|
| Shareholder<br>return | <ul> <li>Buyback</li> <li>Highly flexible way for shareholder return</li> <li>Implemented twice in 2018 (Feb., Nov.)</li> </ul> |




# 2019/12 Forecast

No company acquisitions included, based on ¥105/\$

(Millions of JPY)

| /                                | <u> </u>                        | · · · · · · · · · · · · · · · · · · · |  | , ,                                    | (MINIONS OF JPT) |
|----------------------------------|---------------------------------|---------------------------------------|--|--|------------------|
|                                  | 2018.12<br>(JanDec.)<br>Results | 2019.12<br>(JanDec.)<br>Forecast      | 2019.12<br>H1<br>(JanJun.)<br>Forecast | 2019.12<br>H2<br>(JulDec.)<br>Forecast | YoY              |
| Net sales                        | 207,404                         | 195,000                               | 78,000                                 | 117,000                                | -6.0%            |
| Industrial Materials             | 47,124                          | ,<br>51,800                           | 24,800                                 | 27,000                                 | +9.9%            |
| Devices                          | 123,541                         | 110,600                               | 37,200                                 | 73,400                                 | -10.5%           |
| Medical Technologies             | 22,351                          | 25,000                                | 12,500                                 | 12,500                                 | +11.8%           |
| Information and<br>Communication | 13,935                          | 7,100                                 | 3,300                                  | 3,800                                  | -49.1%           |
| Other                            | 452                             | 500                                   | 200                                    | 300                                    | +10.6%           |
| EBITDA<br>EBITDA Margin          | 17,343<br>8.4%                  | 18,800<br>9.6%                        | 1,080<br>1.4%                          | 17,720<br>15.1%                        | +8.4%<br>+1.2pt  |
| Industrial Materials             | 3,675                           | 4,900                                 | -                                      | -                                      | +33.3%           |
| Devices                          | 14,444                          | 13,200                                | -                                      | -                                      | -8.6%            |
| Medical Technologies             | 1,829                           | 2,400                                 | -                                      | -                                      | +31.2%           |
| Information and<br>Communication | -402                            | 400                                   | -                                      | -                                      | Into black       |
| Other                            | -2,203                          | -2,100                                | -                                      | -                                      | -                |
| Operating Profit                 | 8,071                           | 8,500                                 | -4,000                                 | 12,500                                 | +5.3%            |
| Operating profit margin          | 3.9%                            | 4.4%                                  | -5.1%                                  | 10.7%                                  | +0.5pt           |
| Ordinary Profit                  | 7,370                           | 7,800                                 | -4,300                                 | 12,100                                 | +5.8%            |
| Net Profit                       | 4,308                           | 6,000                                 | -4,000                                 | 10,000                                 | +39.2%           |
| Forex                            | ¥109/\$                         | ¥105/\$                               | ¥105/\$                                | ¥105/\$                                | -                |

## Reference: Capital investment, Depreciation and R&D



\*The straight-line method has been used for the depreciation in the Company and its domestic consolidated subsidiaries since the first quarter ended March 31, 2018

nissha

\* Increased because of the change of the function of some division from production to R&D.

# Reference: Capital investment, Depreciation, M&A investment, Amortization of goodwill, R&D

(Million of JPY)

|                          | FY2018.12 Q1<br>(JanMar.)<br>results | FY2018.12 Q2<br>(AprJun.)<br>results | FY2018.12 Q3<br>(JulSep.)<br>results | FY2018.12 Q4<br>(OctDec.)<br>Results |
|--------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Capital<br>investment    | 3,431                                | 1,745                                | 3,485                                | 1,961                                |
| Depreciation             | 1,955                                | 1,889                                | 1,937                                | 1,891                                |
| M&A<br>investment        | 39                                   | 2,877                                | 79                                   | 659                                  |
| Amortization of goodwill | 388                                  | 376                                  | 460                                  | 375                                  |
| R&D                      | 933                                  | 979                                  | 878                                  | 1,075                                |

\*The straight-line method has been used for the depreciation in the Company and its domestic consolidated subsidiaries since the first quarter ended March 31, 2018.



This document contains confidential information and all rights regarding the document belong to Nissha Group. Therefore, any disclosure and/or leakage of the document to any third parties other than recipients of the documents, and copy, transfer and/or citation of the document without the prior authorization of Nissha Group are strictly prohibited. In addition, any use of the document for the purpose other than original purpose for the disclosure of the document is also prohibited.

本資料には機密情報が掲載され、一切の権利はNISSHAグループに帰属しているので、 NISSHAグループの事前の許可なく、本資料を受領者以外の第三者に開示、漏洩したり、 複写、転送、引用することを固く禁止いたします。また、本資料の開示目的以外での使 用は同様に禁止いたします。

